Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.

David J JacksonGirolamo PelaiaBenjamin EmmanuelTrung N TranDavid CohenVivian H ShihAnat ShavitDouglas ArbetterRohit KatialAdrian Paul J RabeEsther Garcia GilMarisa PardalJavier NuevoMichael WattSilvia BoarinoSheena KayaniyilClaudia Chaves LoureiroAlicia Padilla-GaloParameswaran Nair

Published in: The European respiratory journal (2024)

In this large, real-world programme, SEA patients treated with benralizumab had substantial improvements in clinical outcomes irrespective of previous biologic use and key clinical characteristics important to therapeutic decision-making in clinical practice.

Keyphrases

rheumatoid arthritis
clinical practice
study protocol
chronic obstructive pulmonary disease
lung function
early onset
randomized controlled trial
allergic rhinitis
cystic fibrosis